Patents by Inventor Con Panousis

Con Panousis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING ATHEROSCLEROSIS
    Publication number: 20190309089
    Abstract: The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 10, 2019
    Inventors: Con PANOUSIS, Karlheinz PETER, Hamid HOSSEINI, Yung-Chih CHEN
  • COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
    Publication number: 20190248920
    Abstract: A membrane targeted binding protein that binds to at least one blood coagulation factor, wherein the binding protein has pro-coagulant activity.
    Type: Application
    Filed: September 22, 2017
    Publication date: August 15, 2019
    Inventors: Peter SCHMIDT, Chao-Guang CHEN, Con PANOUSIS, Louis FABRI
  • RECOMBINANT IGG FC MULTIMERS
    Publication number: 20190119377
    Abstract: This disclosure provides recombinant IgG Fc multimers and methods of treating autoimmune and inflammatory diseases by administering such multimers.
    Type: Application
    Filed: January 27, 2017
    Publication date: April 25, 2019
    Inventors: Rolf SPIRIG, Fabian KAESERMANN, Adrian ZUERCHER, Con PANOUSIS, Adriana BAZ MORELLI, Chao-Guang CHEN
  • ANTIBODIES AGAINST G-CSFR AND USES THEREOF
    Publication number: 20190055313
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 21, 2019
    Applicant: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • METHOD OF TREATING CANCER
    Publication number: 20190023783
    Abstract: The present disclosure provides computer-implemented methods of organising the marketing of a compound that neutralises BTN2A1.
    Type: Application
    Filed: July 31, 2018
    Publication date: January 24, 2019
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS
  • MUTATED VON WILLEBRAND FACTOR
    Publication number: 20190016784
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least one modification at a position selected from the group consisting of L18, V42, K149, N248, S279, V320, T325, Q395 and K418 such that the modified polypeptide binds to Factor VIII with an off rate lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Inventors: Arna ANDREWS, Con PANOUSIS, Kerstin EMMRICH, Michael WILSON, Steve DOWER, Matthew HARDY, Dallas HARTMAN
  • MUTATED TRUNCATED VON WILLEBRAND FACTOR
    Publication number: 20190015483
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The polypeptide comprises truncated von Willebrand Factor (VWF) which comprises a sequence as shown in SEQ ID NO:3 or a fragment thereof or a sequence 90% identical thereto, wherein the truncated VWF comprises at least one modification in comparison to SEQ ID NO: 3 in at least one position selected from the group consisting of SI, S3, LI 8, V42, S43, K149, N248, S279, V320, T325, Q395 and K418.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Applicant: CSL BEHRING RECOMBINANT FACILITY AG
    Inventors: Arna ANDREWS, Con PANOUSIS, Kerstin EMMRICH, Michael WILSON, Steve DOWER, Matthew HARDY, Dallas HARTMAN
  • Humanized anti-interleukin 3 receptor alpha chain antibodies
    Patent number: 10047161
    Abstract: The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 14, 2018
    Assignee: CSL Limited
    Inventor: Con Panousis
  • METHODS OF ADMINISTERING INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES
    Publication number: 20180134806
    Abstract: The invention relates to inhibitory anti-factor XII/FXIla antibodies and methods of their use.
    Type: Application
    Filed: November 27, 2017
    Publication date: May 17, 2018
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • METHODS OF TREATING MENINGIOMA
    Publication number: 20180057606
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 1, 2018
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark
  • Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies
    Patent number: 9856325
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
    Patent number: 9856326
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Compositions and methods for targeting type 1 interferon producing cells
    Patent number: 9758585
    Abstract: The present disclosure provides a method for treating lupus, Sjörgen's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor ? (IL-3R?) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: September 12, 2017
    Assignee: CSL Limited
    Inventors: Gino Luigi Vairo, Andrew Nash, Eugene Maraskovsky, Nick Wilson, Samantha Busfield, Con Panousis
  • ANTIBODIES AGAINST G-CSFR AND USES THEREOF
    Publication number: 20170226214
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 10, 2017
    Applicant: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
    Publication number: 20170137536
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 18, 2017
    Applicants: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
    Publication number: 20170121423
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 4, 2017
    Applicants: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Method of cloning nucleic acid
    Patent number: 9617329
    Abstract: The present disclosure provides methods for producing expression constructs comprising linking a plurality of unlinked nucleic acids, including a nucleic acid encoding a marker protein.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: April 11, 2017
    Assignee: CSL Limited
    Inventors: Con Panousis, Chao-Guang Chen
  • METHOD OF TREATING CANCER
    Publication number: 20160376364
    Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.
    Type: Application
    Filed: November 28, 2014
    Publication date: December 29, 2016
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS
  • Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses
    Patent number: 9518127
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 13, 2016
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • SPECIFIC BINDING PROTEINS AND USES THEREOF
    Publication number: 20160046726
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: June 11, 2015
    Publication date: February 18, 2016
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark